Ameriprise Financial Inc. boosted its stake in Amedisys Inc. (NASDAQ:AMED) by 19.5% during the second quarter, Holdings Channel reports. The institutional investor owned 174,275 shares of the company’s stock after buying an additional 28,472 shares during the period. Ameriprise Financial Inc. owned 0.52% of Amedisys worth $8,797,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. purchased a new position in Amedisys during the first quarter valued at approximately $4,834,000. Nuveen Asset Management LLC boosted its stake in shares of Amedisys by 46.2% in the first quarter. Nuveen Asset Management LLC now owns 45,382 shares of the company’s stock valued at $2,193,000 after buying an additional 14,334 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Amedisys by 81.1% in the first quarter. Renaissance Technologies LLC now owns 630,901 shares of the company’s stock valued at $30,498,000 after buying an additional 282,600 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Amedisys by 53.8% in the first quarter. Goldman Sachs Group Inc. now owns 61,584 shares of the company’s stock valued at $2,977,000 after buying an additional 21,535 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Amedisys by 6.3% in the first quarter. State Street Corp now owns 686,983 shares of the company’s stock valued at $33,211,000 after buying an additional 40,819 shares during the last quarter. Institutional investors and hedge funds own 91.45% of the company’s stock.
Amedisys Inc. (NASDAQ:AMED) traded up 0.04% during mid-day trading on Tuesday, hitting $46.74. The stock had a trading volume of 46,656 shares. Amedisys Inc. has a one year low of $31.16 and a one year high of $55.16. The stock has a market cap of $1.57 billion, a P/E ratio of 40.89 and a beta of 0.96. The company has a 50 day moving average price of $48.22 and a 200 day moving average price of $49.82.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Tuesday, August 2nd. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.42. Amedisys had a net margin of 2.78% and a return on equity of 12.17%. The company earned $360 million during the quarter, compared to analysts’ expectations of $353.07 million. During the same period in the previous year, the company earned $0.43 EPS. The business’s quarterly revenue was up 14.8% compared to the same quarter last year. On average, equities analysts anticipate that Amedisys Inc. will post $1.69 EPS for the current year.
Several analysts have recently issued reports on the company. Zacks Investment Research cut Amedisys from a “hold” rating to a “sell” rating in a research note on Monday, July 11th. Jefferies Group reiterated a “buy” rating on shares of Amedisys in a research note on Tuesday, September 6th. Wells Fargo & Co. reiterated a “buy” rating on shares of Amedisys in a research note on Sunday, September 11th. Mizuho cut Amedisys from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $57.00 to $55.00 in a research note on Wednesday, August 3rd. Finally, Stephens assumed coverage on Amedisys in a research note on Thursday, June 16th. They issued an “equal weight” rating and a $55.00 price objective on the stock. Seven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $51.75.
Amedisys Company Profile
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc. (NASDAQ:AMED).
Receive News & Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.